COGT News and Press, Cogent Biosciences Inc Com From 12/02/20

Cogent Biosciences (COGT) has priced 10,256,411 common shares at $9.75/share, for gross proceeds of ~$100M (from $60M).Underwriters over-allotment is an additional 1,538,461 shares.Offering is expected to close on December 4. Net proceeds will be used for development, regulatory and commercia...

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined di...

Gainers: [[NTN]] +20.7%. [[WDC]] +7.9%. [[NCNA]] +7.4%. [[SPCE]] +5.6%. [[JFIN]] +5.4%.Losers: [[MOHO]] -7.9%. [[COGT]] -6.7%. [[FOUR]] -6.7%. [[EMKR]] -6.6%. [[OBLG]] -6.6%. For further details see: NTN, NCNA, MOHO and EMKR among after-hours movers

Thinly traded micro cap Cogent Biosciences (COGT) is under modest pressure after hours in reaction to its $60M public offering of common stock. Price, volume and terms have yet to be announced.Shares down 7%. For further details see: Cogent Bio launches $60M equity offering, shares...

Cogent Biosciences Announces $60.0 Million Public Offering of Shares of Common Stock PR Newswire CAMBRIDGE, Mass., Nov. 30, 2020 CAMBRIDGE, Mass. , Nov. 30, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on devel...

Cogent Biosciences Appoints Brad Barnett as Chief Technology Officer Highly skilled leader in drug development and manufacturing with nearly 20 years of experience at Array BioPharma as Vice President of Supply Chain and Manufacturing PR Newswire CAMBRIDGE, Mass., Nov. 3...

Cogent Biosciences to Participate in 3rd Annual Evercore ISI HealthCONx Virtual Conference PR Newswire CAMBRIDGE, Mass., Nov. 20, 2020 CAMBRIDGE, Mass. , Nov. 20, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company ...

Cogent Biosciences ([[COGT]] +1.2%) has announced final results from Phase 1/2 study evaluating combination of PLX9486 + Pfizer's Sutent  (sunitinib) in patients with advanced gastrointestinal stromal tumors ((GIST)). Data will be presented at the Connective Tissue Oncology Soc...

Cogent Biosciences Announces Final Results from PLX9486 Phase 1/2 Study in Advanced GIST Patients at CTOS 2020 Majority of patients treated with PLX9486 + sunitinib experienced clinical benefit with a median PFS of 12 months and 20% ORR, including a complete response, in a heavi...

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference PR Newswire CAMBRIDGE, Mass., Nov. 12, 2020 CAMBRIDGE, Mass. , Nov. 12, 2020 /PRNewswire/ -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focuse...